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Edited by Robert BaroukiAbstract T cell responses to heat shock proteins (HSP) have
disease suppressive activities through production of anti-inﬂam-
matory cytokines in patients and in models of inﬂammatory dis-
eases. There is evidence that the anti-inﬂammatory activity of
HSP-speciﬁc T cells depends on their recognition of endogenous
HSP epitopes as expressed by stressed cells at sites of inﬂamma-
tion. Previously, we have demonstrated that such T cells can be
induced by conserved sequences of microbial HSP. Now we pro-
pose that drug induced up-regulation of endogenous HSP can
contribute to anti-inﬂammatory T cell regulation.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Immuno-therapy1. Cell stress leads to HSP up-regulation
Heat shock protein (HSP) expression can be induced in cells
through various forms of stress, such as hyperthermia (fever),
nutrient starvation, oxidative- and toxic stress and exposure to
inﬂammatory cytokines [1,2]. On the basis of their molecular
weights, HSP can be organized in HSP families, including
the HSP100, HSP90, HSP70, HSP60, HSP40 and the small
heat shock protein families [3]. Most likely because of their
critical signiﬁcance for cell survival under conditions of stress,
the primary structures of many individual members of the HSP
families remained highly conserved throughout evolution. For
some HPS family members expression is mainly constitutive
and for others the expression is highly inducible. Depending
on the cell type and applied stress, protein expression of induc-
ible HSP family members is increased. The inducible HSP70
family members are among the most prominent proteins up-
regulated under stress. In addition, the expression of HSC70
is an example of constitutive HSP expression [1,4,5].Abbreviations: HSP, heat shock protein or proteins; HSF, heat shock
factor; HSR, heat shock response; FR-WBH, fever-range whole body
hyperthermia; GALT, gut associated lymphoid tissue; GGA, geranyl-
geranyl acetone; PG, proteoglycan; IL10, interleukin-10; EAE, exper-
imental allergic encephalomyelitis; JIA, juvenile idiopathic arthritis
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doi:10.1016/j.febslet.2007.04.082Upon stress, augmented expression of HSP is controlled by a
family of heat shock transcription factors (HSFs) among
which HSF1 is essential for induction of the so-called heat
shock response (HSR). Under physiologic conditions HSF1
is maintained in its monomeric, inactive form by binding to
molecular chaperones like HSP70 and HSP90. After stress,
HSF1 is released and translocates to the nucleus. Subse-
quently, trimerization, binding to heat shock elements (HSE)
and hyperphosphorylation ﬁnally result in transcription of
HSPs [6,7]. Since altered HSP function has been associated
with the development of several diseases, including immune
dysfunctions [8], compound induced modulation of HSP
expression became an emerging ﬁeld of drug development
and will be discussed brieﬂy below. We will focus on com-
pounds that can be administered orally, since the intestinal
mucosa seems most relevant for induction of T cell immuno-
regulation. In addition, up-regulation of HSP by hyperthermia
will be discussed.
The enhanced HSP induction through compounds which we
discuss can obviously be of relevance for aging, as elderly indi-
viduals have a known reduced HSP inducibility [9,10]. In this
way such artiﬁcial HSP enhancement could counter the age
dependent increased risk of autoimmune diseases, which is a
possible reﬂection of the growing dysbalances of the immune
system during senescence (see Fig. 1).2. Several drug related compounds are HSP expression
enhancers
Activators of HSF can be categorized into HSP inducers and
co-inducers. An inducer activates HSF in the absence of addi-
tional stress. A co-inducer partially activates components of
the HSR, further stress signals are required for full activation
of HSP transcription [11,12].
Compounds that inhibit HSP90 can act as HSP inducers.
HSP90 inhibitors, like the benzoquinone ansamycins herbamy-
cin A and geldanamycin, have been shown to bind to HSP90
ensuing in a disturbance in the binding of HSP90 to HSF.
Then, released HSF is further activated leading to HSP expres-
sion [13,14].
Non-steroidal anti-inﬂammatory drugs (NSAIDS) can
co-induce HSP expression. Sodium salicylate induces trimer-


















Fig. 1. HSP inducing and co-inducing compounds enhance the
expression of HSP in tissue cells, including MHCII (major histocom-
patibility complex) positive cells which then present HSP epitopes to
HSP-speciﬁc CD4+ T cells. A variety of mechanisms [39] (microbial
HSP exposure in the tolerising gut mucosa; presentation by non-
professional antigen presenting cell (APC) lacking co-stimulatory
molecules; HSP acting as partial agonist; priming in the presence of
stress cytokines such as IL10) are imposing a regulatory phenotype on
these CD4+ T cells. These HSP-speciﬁc regulatory T cells can
recognize induced HSP as presented by stressed cells at the site of
inﬂammation and dampen inﬂammation by production of suppressive
cytokines such as IL10. And also here the HSP inducing compounds
can further enhance local HSP expression.
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ycilate, can induce both DNA binding and hyperphosporyla-
tion [16]. In the search for non-toxic HSP inducing
compounds, ample attention was paid to herbal medicines.
Several of them are known for their anti-inﬂammatory and
anti-tumour eﬀects. Celastrol, a member of the triterpene fam-
ily of compounds, has been shown to activate HSF1 with
kinetics similar to that of heat stress. Moreover, Celastrol
can amplify heat shock induced HSP expression [17]. The her-
bal medicine constituents, glycyrrhizin and paeoniﬂorin, were
reported to have an enhancing eﬀect on HSP expression. Gly-
cyrrhizin was acting as a co-inducer. In contrast, Paeoniﬂorin
could induce HSP expression without supplementary stress
[18].
Curcumin, the major compound of the seasoning tumeric,
was described to increase HSP27, aB crystallin and HSP70
expression in combination with arsenite or heat stress. In con-
trast, treatment with curcumin alone did not have an eﬀect on
HSP expression. The elevated HSP expression was seen in both
cultured cells and after in vivo administration, in rat tissues
[19]. The hydroxyl amine derivates, arimoclomol and bimoclo-
mol have been suggested to co-induce HSP expression. Arimo-
clomol induces Hsp70 and Hsp90 expression [20]. Bimoclomol
has been reported, to have cytoprotective eﬀects by up regula-
tion of HSPs in several in vivo and in vitro models [21–23].
Anti-ulcer drugs like geranyl geranyl acetone (GGA), rebamip-
ide and carbenoxolone can induce or co-induce HSPs. Among
the anti-ulcer drugs GGA, an acrylic isoprenoid, is best de-scribed. Oral treatment with GGA protected from ischemia
reperfusion induced liver injury via HSP up-regulation [24].
Depending on the cell type GGA can either act as an inducer
or a co-inducer. Recently, GGA has been described to bind to
HSP70 leading to dissociation of HSP70 from HSF after which
free HSF could bind to DNA [25].3. Hyperthermia induced HSP up-regulation
Hyperthermia pre-treatment can induce thermo-tolerance
and has been shown to be protective against various types of
injury. HSP up-regulation upon heat shock is extensively stud-
ied in multiple cell lines, primary cell cultures and in vivo mod-
els. HSP up-regulation and the kinetics thereof seem to depend
very much on cell type and heat shock conditions used.
In conventional models for in vivo hyperthermia, a short
heat treatment, 15–20 min, is applied at relatively high temper-
ature (42–43 C). Heat preconditioning of rats at 42 C for
15 min, attenuates acute ischemic renal injury. In the latter
study, protein expression of HSP70 but not HSP27, HSP32
and HSP90 was signiﬁcantly increased. Administration of
quercitin, an HSP70 inhibitor, almost completely reversed pro-
tection [26]. Ostberg et al. propose that fever-range whole body
hyperthermia (FR-WBH, 39.5–40 C for 6 h) is a more accu-
rate model for heat stress than the conventional models be-
cause it more closely mimics physiological conditions. In this
model up-regulation of HSP70 and HSP110 was found in mul-
tiple mouse tissues [27]. Likewise, we could detect increased
Hsp70 but not Hsp60 expression after 6 h in vivo FR-WBH
in spleen cells of mice (unpublished results).4. HSP inducing compounds can be anti-inﬂammatory by
inhibiting NF-jB
Many compounds that (co-)induce the heat shock response
(HSR) are also NF-jB inhibitors. In the non-inﬂammatory
state NF-jB is kept inactive in its cytosolic form complexed
to its inhibitor I-jBa. Firstly, proteasome inhibitors prevent
degradation of I-jBa by the proteasome and thereby prevent
activation of NF-jB and its translocation to the nucleus. At
the same time proteasome inhibition increases the cytosolic
content of incorrectly folded proteins, thereby inducing the
HSR.
Secondly, many inducers of the HSR are known to block the
NF-jB pathway directly not only by stabilizing I-jBa but also
by inducing I-jBa gene expression [28]. Therefore, various
compounds may act in an anti-inﬂammatory fashion directly
in the cell by blocking the pro-inﬂammatory NF-jB cascade,
but simultaneously through the induction of the HSR thereby
evoking immune modulation by the provision of targets for
HSP-speciﬁc regulatory T cells.5. Endogenous cell stress induced HSP at the site of
inﬂammation are targets of regulatory T cells
The role of heat shock proteins in experimental models of
inﬂammatory diseases was ﬁrst discovered in the model of
adjuvant induced arthritis in rats [29]. Disease associated T cell
lines and clones raised against heat-killed mycobacteria, the
disease triggering antigen in this model, were found to
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mette Guerin) with a molecular weight of 65 kDa. This
65 kDa protein turned out to be the HSP60 of mycobacteria.
Interestingly, immunization studies with this recombinant pro-
tein in the same rat arthritis model showed that HSP60 immu-
nized animals developed a resistance against the induction of
adjuvant arthritis.
Steve Anderton [30] was able to generate a series of T cell
lines from rats after immunization with mycobacterial
HSP60. These T cells were tested in adoptive transfer experi-
ments and one of them was transferring resistance. This partic-
ular T cell line was found to recognize a highly conserved
sequence of HSP60 and as expected, this T cell did cross-recog-
nize the mammalian homologue of the mycobacterial protein:
rat HSP60. The other T cells that did not transfer resistance
were also mapped and none of them cross-recognized mamma-
lian HSP60.
The same was also found for mycobacterial HSP70 [31].
Immunization with mycobacterial HSP70 protected against
adjuvant arthritis in rats, and also protected in a model in-
duced with a synthetic oily compound called avridine. Also
here mapping studies revealed that only T cells recognizing
highly conserved sequences were transferring protection and
were cross-responding to the mammalian homologous pro-
teins. Various studies using diﬀerent routes of exposure to pep-
tides representing conserved HSP60 and HSP70 T cell
epitopes, have shown immuno-regulatory eﬀects of these con-
served sequences in a multitude of disease models.
From these studies we must conclude that immune exposure
to microbial HSP was capable of inducing a regulatory T cell
response and that such regulation depended on a T cell re-
sponse that included a repertoire of (endogenous) self-HSP-
speciﬁc T cells.
The existence of self-HSP reactive T cells has been demon-
strated in many diﬀerent studies, even in human umbilical
cord lymphocytes [32] and in mice transgenic for HSP60
[33]. Apparently, thymus selection allows such a repertoire
to develop. Microbial HSP are dominantly immunogenic
and frequencies of HSP-speciﬁc T cells can be very high fol-
lowing microbial exposure. It makes sense to suppose that this
T cell stems from a repertoire that has been selected in the
thymus by self (endogenous) HSP peptides. Low aﬃnity inter-
actions for such self-HSP must have stimulated positive selec-
tion and must have allowed the self-HSP reactive T cells to
survive negative selection. In the peripheral immune system,
when the cells have left the central lymphoid organs, micro-
bial HSP can be the full agonists for these T cells compatible
with the immuno-dominant character of these HSP. At the
same time, when self-HSP is expressed in the periphery, under
conditions of cell stress, the self HSP can act as a partial ago-
nist producing a regulated or actively regulatory response in
these T cells .
In addition, at the site of inﬂammation HSP will be up-reg-
ulated in all (stressed) cells of which the majority will be tissue
cells lacking co-stimulatory molecules. In the absence of
co-stimulatory molecules T cells will adopt a state of anergy
or regulation [34]. Through these mechanisms HSP-speciﬁc T
cells can adopt a regulatory phenotype upon antigen recogni-
tion in the periphery of the immune system. And this may
explain the tolerant state of these cells and that they can
be present at high frequencies without causing damage. It
is possible that this tendency of these cells to stay in a toler-ant or regulatory state is further promoted by mucosal toler-
ance in the gut associated lymphoid system (GALT)
for abundantly present microbial HSP from the gut ﬂora.
The tolerance for this collection of HSP in the gut microbi-
ota will be dominated by tolerance for the conserved se-
quences, as these are shared among the variety of bacterial
species present. Thus, there may be a natural focus on the con-
served sequences of HSP to drive a repertoire of regulatory T
cells.
In various studies HSP reactive T cells have been seen to
produce the immuno-regulatory cytokine interleukin-10
(IL10) [35–37]. These cells are most likely regulatory T cells,
induced in the periphery and reﬂecting mechanisms known
to contribute to development of peripheral tolerance.
Some studies have also suggested that HSP are antigens seen
by natural T regs [38]. Along the same line, studies in children
with juvenile idiopathic arthritis (JIA) and adults with rheuma-
toid arthritis (RA) have indicated the potential of HSP to trig-
ger in T cells the presence of FoxP3 which is a marker for
natural T regs.
Thus, given the fact that regulatory T cells induced by
microbial HSP have been seen to cross-recognize endogenous
HSP through their speciﬁcity for conserved HSP sequences,
it seems that up-regulated endogenous HSP in stressed cells
is the target and the possible initiator of the local regulatory
activity of these T cells.
How levels of endogenous expression of HSP at sites of
inﬂammation or elsewhere in the body would inﬂuence that
capacity of endogenous HSP reactive T cells to maintain or
display regulatory activity is unknown.
Experimental manipulation of endogenous HSP expression,
during disease or during maturation of the immune system
may well lead to a further understanding of the possible con-
tribution of cellular HSP expression to T cell mediated im-
mune regulation.
Some drug compounds are known to have eﬀects on endog-
enous HSP levels as discussed above. In the following section
we will discuss some eﬀects of such compounds in disease mod-
els with T cell involvement.6. Administration of HSP up-regulators and eﬀects on T cells in
chronic inﬂammatory diseases
Earlier we described that T cells can respond to endogenous
HSP and that this can lead to an anti-inﬂammatory phenotype.
In other words, HSP up-regulated in inﬂamed tissues can be
targets for HSP-speciﬁc regulatory T cells [39]. A relative deﬁ-
ciency of this protective activity in chronic inﬂammatory dis-
eases can be due to a reduction of the HSP reactive T cell
population itself or to a relatively low expression of HSP in
the inﬂamed tissue where HSP are required as targets for trig-
gering the regulatory T cells locally. Elsewhere we have
reviewed how administration of (immunization with) HSP
can reinforce the regulatory HSP-speciﬁc T cells [39]. Here
we will present examples from the literature in which (co-
)inducers of HSP may have enhanced the expression of HSP
to serve as better targets for the HSP-speciﬁc regulatory T cells
capable of inhibiting T cell mediated chronic inﬂammatory dis-
eases. Additionally, enhanced expression in non-inﬂamed tis-
sues also may have reinforced the induction of HSP-speciﬁc
regulatory T cells.
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GGA, a speciﬁc HSP (co-)inducer, is given to patients for
anti-ulcer therapy, its mode of action being local gastric pari-
etal cell protection. In the experimental model of autoimmune
uveoretinitis (EAU) in mice GGA treatment reduced disease
which was associated with suppressed T cell responses against
the disease inducing antigen, IRBP peptides 1–20 [40]. GGA
was also found to be protective in trinitrobenzene sulfonic
acid-induced (TNBS) colitis [41], a T cell mediated model for
colitis and in dextran sulfate sodium-induced (DSS) colitis in
mice [42].6.2. Curcumin
Curcumin is a biologically active component of turmeric,
inhibits NF-jB and is known to be a co-inducer of stress pro-
teins [19]. Recently, a turmeric extract containing curcumin,
given orally was shown to inhibit joint inﬂammation and per-
iarticular joint destruction in a dose-dependent manner in the
T cell mediated, experimental model of streptococcal cell wall-
induced arthritis [43]. Also, an anti-arthritic eﬀect of curcumin
has been reported in one small clinical study of rheumatoid
arthritis (RA) and in other studies of arthritis in animals
[44,45]. In other patient studies oral curcumin was found to
be a safe medication for maintaining remission in quiescent
ulcerative colitis [46] and it induced improvements in other
forms of inﬂammatory bowel disease [47].
Recently, it has been suggested that curcumin’s reported
beneﬁcial eﬀects in arthritis and colitis, but also in other T cell
mediated chronic inﬂammatory disorders like allergy, asthma,
atherosclerosis and diabetes, might be due in part to its ability
to modulate the immune system, and that these ﬁndings war-
rant further consideration of curcumin as a therapy for im-
mune disorders [48].6.3. Geldanamycin
Geldanamycin by its direct binding to HSP90 activates the
HSR response and induces HSP, and at the same time, inhibits
NF-jB by inducing selective degradation (through autophagy)
of the IkappaB kinase (IKK). IKK normally phosphorylates
I-jB, which then detaches from cytosolic NF-jB enabling
translocation to the nucleus of the latter [49].
Administration of 17-allylamino-17-demethoxygeldanamy-
cin (17-AAG), a less toxic derivative of the naturally occurring
geldanamycin, in mice immunized with myelin oligodendro-
cyte glycoprotein peptide to induce experimental autoimmune
encephalomyelitis (EAE), prevented disease when given at an
early time, and reduced clinical symptoms when given during
ongoing disease. T cells from treated mice showed a reduced
response to immunogen re-stimulation [50].6.4. Hyperthermia
In EAE whole body hyperthermia (WBH) has been de-
scribed to strongly reduce the incidence and severity of EAE
[51]. T-cell activation, assessed by the production of interferon
gamma (IFN-c) in response to the EAE inducing immunogen
myeloid oligodendrocyte antigen (35–55), was also decreased
by the HSR.
Thus, in several disease models endogenous HSP induction
has been seen to lead to suppression of disease. Although
mechanisms involved could be manifold, in some cases evi-
dence for immuno-modulatory eﬀects was already obtained.7. HSP induction and the possible contribution of mucosal
tolerance to immuno-regulation
Most HSP inducers are administered orally. Therefore, we
have to consider the eﬀects of these drugs in inducing local
HSP up-regulation in the mucosal tissues.
The mucosal immune system, as present for example in the
gastrointestinal tract and airways, guards the major entry sites
of the body against foreign antigens, and is thereto especially
equipped with the ability to adjust the outcome of the immune
response depending on the type of antigen encountered. The
speciﬁc down regulation of unwanted and unnecessary sys-
temic immune responses to innocuous antigens upon mucosal
antigen encounter is called mucosal tolerance and has been de-
scribed for both the intestinal and the respiratory mucosa
[52,53]. This systemic immunological hypo-responsiveness is
characterized by a reduced T and/or B cell response to the anti-
gen ﬁrstly applied at the mucosal surface. A major mechanism
contributing to mucosal tolerance is the active induction of
antigen speciﬁc regulatory T cells, characterized by the secre-
tion of regulatory cytokines such as IL-10 [53,54].
Mucosal application of bacterial HSPs has been shown to be
a potent means of regulatory T cell induction in several models
of chronic inﬂammatory diseases such as atherosclerosis,
arthritis and diabetes [31,55]. Since up-regulation of self-HSPs
is part of the inﬂammatory response in these diseases, the
induction of self-HSP-cross-reactive T cells upon mucosal
application of the highly homologous bacterial HSP might
seem an attractive explanation for the development of the
mucosally induced regulatory T cells with speciﬁcity for other-
wise very immunogenic and potentially pro-inﬂammatory
bacterial proteins. Indeed, in several studies of the protec-
tive mechanism of HSP, self-HSP cross-reactive T cells were
found to produce regulatory cytokines, such as IL-10 and
exhibit regulatory activity (Wieten et al. in prep, [31,56]). In
addition, mycobacterial HSP70 mediated protection in the
experimental mouse model of proteoglycan induced arthri-
tis not only induced IL10 producing HSP-speciﬁc T cells, but
also proteoglycan-speciﬁc T cells that produced IL-10 upon
antigen speciﬁc stimulation (Wieten et al. unpublished results).
This indicated that bacterial-HSP application induced a regu-
latory phenotype in both HSP speciﬁc and disease associated
proteoglycan (PG)-speciﬁc T cells. These data imply that HSPs
might be a therapeutic target for the induction of mucosal
tolerance in cases where the auto-antigen is unknown and
that microbial HSP can induce antigen speciﬁc regulatory
T cells.
Various mechanisms have been described to be important in
the suppressive function of regulatory T cells. In the case of
HSP-speciﬁc regulatory T cells it is attractive to speculate that
these cells play an important role at the site of inﬂammation
where self-HSP is abundantly present. Mucosal HSP-speciﬁc
regulatory T cells can dampen the ongoing inﬂammatory re-
sponse by local production of IL-10 at the site of inﬂammation
thereby down-regulating pro-inﬂammatory cells and cyto-
kines. In addition, mucosal regulatory T cells have been shown
to use infectious tolerance as a mechanism to expand their reg-
ulatory function and convert naı¨ve T cells to diﬀerentiate into
regulatory T cells [57]. Such a mechanism might explain the
observed IL-10 production by arthritogenic T cells in the pro-
teoglycan induced arthritis model and might expand the regu-
lation to diﬀerent cells or antigens involved in the
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also play a role during the dampening of the inﬂammatory re-
sponse under normal conditions thereby preventing excessive
inﬂammation and subsequent organ damage.
For the reasons given above, the exposure to (microbial)
HSP at the mucosal surface of the gut, may be a major factor
in endowing the repertoire of HSP-speciﬁc T cells with regula-
tory potential. A local action of our HSP inducing compounds
at the gut mucosa, in up-regulating endogenous self-HSP in
the mucosa may therefore prepare the mucosa for attracting
the attention of HSP-speciﬁc T cells and for creating a local
environment optimal for setting these T cells into a regulatory
mode.8. Clinical development of HSP mediated immune intervention
in chronic inﬂammatory diseases
Studies in JIA have shown that T cell responses to human
HSP60 are predominantly found in patients with remitting
forms of this disease (oligo-articular). In addition remission
was shown to be preceded by raised proliferative responses
to human HSP60. In a recent study Kamphuis et al. [37] have
shown that such patients do respond to conserved HSP60 se-
quences and that the T cells of such patients do produce high
levels of IL10.
First human trials have conﬁrmed the immuno-modulatory
capacity of HSP-derived peptides in chronic autoimmunity.
In type 1 diabetes a mammalian HSP60 peptide – diaPep277 –
comprizing a known T cell epitope in mice and humans has
been used to immunize subcutaneously. This procedure was
seen to temporarily arrest inﬂammation and beta-cell destruc-
tion in the pancreas resulting in a decreased insulin depen-
dency. In the peptide speciﬁc T cells the inﬂammatory
cytokine phenotype was seen to shift into the development of
a regulatory (IL10 and IL4) cytokine phenotype [37,58,59].
The therapeutic potential of mucosal delivery of HSP pep-
tides was indicated by a study in RA, where a DnaJ (HSP70
complex) peptide was given orally. Also here a shift towards
a regulatory cytokine proﬁle was noted in the peptide speciﬁc
T cells. In a recent follow-up phase II trial a favorable clinical
response was seen in the peptide treated group especially when
the peptide was given in combination with hydroxychoroqu-
ine, a second line anti-rheumatic drug known to improve anti-
gen presentation (Albani et al., personal comm.). Although in
their infancy, based on ﬁrst results, these HSP directed antigen
speciﬁc approaches are promising and may lead to future eﬀec-
tive therapies for the control of a wide spectrum of inﬂamma-
tory diseases. If so, an important issue to address will be
whether or not such interventions can lead to permanent
remissions of disease. It may well be possible, that the result
of such interventions will be determined, amongst others, by
the continued exposure of the immune system to the relevant
antigens, HSP in this case. As long as we are not aware of
the exact factors that have led to the induction of disease or
that have prepared the ground for disease producing immune
deregulation, we must entertain the possibility that promotion
of stress inducibility of endogenous HSP will be essential for
the (permanent) establishment of disease suppressing immune
regulation. The use of oral HSP up-regulating compounds
for this purpose is then an attractive and further to be explored
possibility.References
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